| Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7.Lab Invest | PMID 38154497无 PMCID | 2024-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial.Lancet Respir Med | PMID 38184008无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.Eur Urol | PMID 38185538PMC11859717 | 2024-Apr | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| The antioxidant and anti-inflammatory activities of avasopasem manganese in age-associated, cisplatin-induced renal injury.Redox Biol | PMID 38215546PMC10821164 | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Anaesthetic efficacy and postinduction hypotension with remimazolam compared with propofol: a multicentre randomised controlled trial.Anaesthesia | PMID 38221513无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prusogliptin (DBPR108) monotherapy in treatment-naïve patients with type 2 diabetes: A randomized, double-blind, active and placebo-controlled, phase 3 study.Diabetes Obes Metab | PMID 38221859无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants.Int J Infect Dis | PMID 38242195无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study.J Gastroenterol Hepatol | PMID 38251791无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Reply of the Authors: Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.Fertil Steril | PMID 38266801无 PMCID | 2024-Apr | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial.Radiother Oncol | PMID 38278333无 PMCID | 2024-Apr | 0.80 | The record describes a randomized phase 3 trial for prostate cancer (oncology, human), but it reports only toxicity outcomes (acute and late gastrointestinal and urinary toxicity) as primary and secondary endpoints. It does not report survival, progression, recurrence, death, hazard, or other time-to-event efficacy outcomes required for inclusion in this Kaplan-Meier digitization cohort. | 待处理 |
| Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy.Expert Opin Drug Discov | PMID 38281068无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study.J Womens Health (Larchmt) | PMID 38301149无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder.Psychiatry Res | PMID 38350291无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial.Lancet Neurol | PMID 38364831无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.Lancet Gastroenterol Hepatol | PMID 38364832无 PMCID | 2024-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial.Clin Endocrinol (Oxf) | PMID 38368603无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.Eur J Cancer | PMID 38402687无 PMCID | 2024-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Randomized, Phase 3, Double-Blind, Crossover Comparison of Multilayer, Extended-Release Methylphenidate (PRC-063), and Lisdexamfetamine in the Driving Performance of Young Adults With ADHD.J Atten Disord | PMID 38404033PMC10981171 | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis.Eur J Heart Fail | PMID 38439585无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.Gynecol Oncol | PMID 38490057无 PMCID | 2024-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Neurol | PMID 38508835无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| High-Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults.Influenza Other Respir Viruses | PMID 38569647PMC10990679 | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial.J Diabetes | PMID 38584148PMC10999497 | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial.Mod Rheumatol | PMID 37436828无 PMCID | 2024-Mar-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.RMD Open | PMID 38531621PMC10966800 | 2024-Mar-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.J Immunother Cancer | PMID 38531663PMC10966812 | 2024-Mar-26 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial.J Headache Pain | PMID 38528476PMC10964539 | 2024-Mar-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.Lancet | PMID 38402887PMC10985839 | 2024-Mar-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.Lancet | PMID 38461841无 PMCID | 2024-Mar-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.Lancet | PMID 38461843无 PMCID | 2024-Mar-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ribociclib plus Endocrine Therapy in Early Breast Cancer.N Engl J Med | PMID 38507751无 PMCID | 2024-Mar-21 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.Clin Infect Dis | PMID 38036487PMC10954327 | 2024-Mar-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.J Clin Oncol | PMID 38232341无 PMCID | 2024-Mar-20 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials.BMJ Open | PMID 38508632PMC10952937 | 2024-Mar-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging-Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized Trial.Int J Radiat Oncol Biol Phys | PMID 37871887无 PMCID | 2024-Mar-15 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Physician- and Patient-Reported Outcomes of the MC1635 Phase 3 Trial of Ultrahypofractionated Versus Moderately Hypofractionated Adjuvant Radiation Therapy After Breast-Conserving Surgery.Int J Radiat Oncol Biol Phys | PMID 37914139无 PMCID | 2024-Mar-15 | 0.95 | The study is a randomized Phase III oncology trial but does not meet the inclusion criteria because the intervention is radiation therapy (non-drug) and the primary endpoints are toxicity and cosmesis, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or a Kaplan-Meier/HR analysis. | 待处理 |
| Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children.J Clin Endocrinol Metab | PMID 37930757PMC10940263 | 2024-Mar-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy in asthma.Thorax | PMID 38160049无 PMCID | 2024-Mar-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia.Parasit Vectors | PMID 38491528PMC10943894 | 2024-Mar-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| High Risk of New HPV Infection Acquisition Among Unvaccinated Young Men.J Infect Dis | PMID 38012959PMC10938197 | 2024-Mar-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes.N Engl J Med | PMID 38477988无 PMCID | 2024-Mar-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.J Immunother Cancer | PMID 38485189PMC10941196 | 2024-Mar-13 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.Neurology | PMID 38330285PMC11067700 | 2024-Mar-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial.Nat Commun | PMID 38461323PMC10925021 | 2024-Mar-09 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma.Cancer Res Commun | PMID 38363156PMC10919207 | 2024-Mar-07 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine.Vaccine | PMID 38365482无 PMCID | 2024-Mar-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Clot Burden Score on Safety and Efficacy of Intravenous Alteplase Prior to Mechanical Thrombectomy in Acute Ischemic Stroke: A Subgroup Analysis of a Randomized Phase 3 Trial.AJNR Am J Neuroradiol | PMID 38388688PMC11286111 | 2024-Mar-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.N Engl J Med | PMID 38393328无 PMCID | 2024-Mar-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.N Engl J Med | PMID 38446675无 PMCID | 2024-Mar-07 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Early Enzymatic Burn Debridement: Results of the DETECT Multicenter Randomized Controlled Trial.J Burn Care Res | PMID 37715999无 PMCID | 2024-Mar-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |